Treatment of cancer could become possible with adenovirus

[2018-04-19] An international team of researchers led by professor Niklas Arnberg at Umeå University, shows that adenovirus binds to a specific type of carbohydrate that is overexpressed on certain types of cancer cells. The discovery opens up new opportunities for the development of virus-based cancer therapy. The study is published in the latest issue of the scientific journal "Proceedings of the National Academy of Sciences of USA",  PNAS April 19, 2018.

Adenovirus is a common virus that causes infectious diseases of the respiratory tract, eyes and gastrointestinal tract in humans and animals. Researchers at Umeå University study molecular mechanisms of infection in order to understand how adenovirus causes disease.
The researchers in Umeå, together with research groups from Germany, the UK and Hungary, have now discovered a new type of mechanism used by a rare adenovirus type to attack cells.

Read more: Treatment of cancer could become possible with adenovirus

Oliver Billker appointed new Director of MIMS

[2018-04-17] MIMS proudly announces that Dr. Oliver Billker from the Wellcome Sanger Institute, Cambridge, UK, has been recruited as future director of MIMS. Dr. Oliver Billker is a distinguished expert in malaria parasite genomics. In October 2018, he will succeed the founding Director of MIMS, Professor Bernt Eric Uhlin, who has held the role since 2007.

The search committee, which was led by the chair of the MIMS Executive Board, Professor Carl-Henrik Heldin, also included Professor Iain Mattaj, Director General for EMBL (European Molecular Biology Laboratory).
“I am very pleased that Dr. Oliver Billker has accepted to be the next director of MIMS,” says Professor Carl-Henrik Heldin.
“With his outstanding scientific credentials, extensive international network and excellent leadership skills, he is the perfect person to lead this very successful institute.”

“Oliver Billker is an excellent choice to lead MIMS”, adds Professor Iain Mattaj.
“His experience in the large-scale genetics and genomics of malaria parasites and his participation in international collaborations will be valuable additions to the MIMS portfolio”.

Read more: Oliver Billker appointed new Director of MIMS

Carl-Henrik Heldin and Oliver Billker receive ERC Advanced Grants

Two ERC Advanced Grants which have recently been awarded by the European Research Council (ERC) have a close relation to MIMS.

One € 2.5 million grant for a period of 5 years will the chair of the MIMS Executive Board professor Carl-Henrik Heldin receive for his project "Pro-tumorigenic effects of TGFb - elucidation of mechanisms and development of selective inhibitors". The second grant was awarded to Umeå University and to the recently appointed new MIMS Director Dr. Oliver Billker for his project: ”Sex in malaria parasites - from genome scale functional gene profiling to transmission blocking intervention targets”. Billker will start his lab at MIMS from 1st of October 2018. Congratulations to both grantees!

More information:
The ERC Advanced Grant (Press Release by the ERC 2018-04-06)
Webpage of Dr. Oliver Billker's laboratory
Webpage of Professor Carl-Henrik Heldin
Press release of Umeå University (only published in Swedish)
(Pictures: Uppsala University and private)

Battling antibiotic resistance

Scientists from MIMS and UCMR contributed to the movie "Battling antibiotic resistance" produced by the Knut and Alice Wallenberg Foundation.

Meet Umeå scientists Felipe Cava, Maria Fällman, Fredrik Almqvist, Elisabeth Sauer-Eriksson and Jörgen Johansson and MIMS Board member Birgitta Henriques Normark and their research on new antimicrobial strategies to fight antibiotic resistance.

Movie published by the Knut and Alice Wallenberg Foundation, 20 February 2018.

Details of antibiotic resistance mechanisms revealed in hospital-acquired drug-resistant pathogens

[2018-03-02] A new paper published by the research groups of Gemma Atkinson and Vasili Hauryliuk at Umeå University resolves years of uncertainty about how the widespread antibiotic resistance factors in the protein group ABCF family confer resistance to lincosamide antibiotics, often used in treatment of infections caused by staphylococci, streptococci and anaerobic bacteria.

Antibiotic resistance is one of the biggest threats to global health, food security, and development today and the new antimicrobial strategies are urgently needed. Scientists at the Umeå Centre for Microbial Research (UCMR) and at The Laboratory for Molecular Infection Medicine Sweden (MIMS) study therefore also antibacterial resistance mechanisms in order to develop new therapeutic strategies against resistant bacteria. The researchers solved recently a mystery in antibiotic resistance research and published their findings in the journal Nucleic Acids Research, which specialises in leading edge research into nucleic acids such as DNA and RNA, and the proteins with which they interact.

Read more: Details of antibiotic resistance mechanisms revealed in hospital-acquired drug-resistant pathogens